Segment and Other Information (Tables)

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Summary of Net Sales by Medicine for Reportable Segments

The following table reflects net sales by medicine for the Company’s reportable segments for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three Months Ended June 30				Six Months Ended June 30
	2020		2019		2020		2019
TEPEZZA	$	165,936	$	—	$	189,387	$	—
KRYSTEXXA		75,201		79,801		168,450		132,058
RAVICTI		65,550		50,441		126,738		100,344
PROCYSBI		41,357		41,174		79,700		80,745
ACTIMMUNE		28,299		29,276		54,840		51,022
BUPHENYL		2,846		2,368		5,160		5,138
QUINSAIR		59		170		336		338
Orphan segment net sales	$	379,248	$	203,230	$	624,611	$	369,645
PENNSAID 2%		35,048		51,472		76,611		101,661
DUEXIS		27,798		30,066		59,145		59,523
RAYOS		14,459		20,284		32,668		39,708
VIMOVO		6,226		14,616		25,653		28,659
MIGERGOT		—		979		—		1,822
Inflammation segment net sales	$	83,531	$	117,417	$	194,077	$	231,373
Total net sales	$	462,779	$	320,647	$	818,688	$	601,018

Summary of Reconciliations of Segment Operating Income

The table below provides reconciliations of the Company’s segment operating income to the Company’s total income (loss) before expense (benefit) for income taxes for the three and six months ended June 30, 2020 and 2019 (in thousands):

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2020			2019			2020			2019
Segment operating income:
Orphan	$	151,541		$	63,696		$	205,897		$	100,400
Inflammation		38,096			60,500			90,038			111,919
Reconciling items:
Amortization and step-up:
Intangible amortization expense		(66,749	)		(57,683	)		(125,324	)		(115,100	)
Inventory step-up expense		—			25			—			(90	)
Acquisition/divestiture-related costs		(46,988	)		(73	)		(47,272	)		(1,275	)
Share-based compensation		(27,057	)		(21,367	)		(83,478	)		(48,915	)
Loss on debt extinguishment		(17,254	)		(11,878	)		(17,254	)		(17,464	)
Interest expense, net		(18,571	)		(22,033	)		(35,915	)		(49,563	)
Depreciation		(6,907	)		(1,443	)		(14,072	)		(2,916	)
Upfront, progress and milestone payments related to license and collaboration agreements		(3,000	)		(4,000	)		(3,000	)		(6,000	)
Impairment of long-lived asset		(1,072	)		—			(1,072	)		—
Loss on sale of assets		—			(10,963	)		—			(10,963	)
Charges relating to discontinuation of Friedreich's ataxia program		—			(1,300	)		—			(1,221	)
Fees related to refinancing activities		—			(1,033	)		(54	)		(1,175	)
Litigation settlements		—			(1,000	)		—			(1,000	)
Drug substance harmonization costs		—			(234	)		(290	)		(314	)
Restructuring and realignment costs		—			(13	)		—			(33	)
Foreign exchange gain		283			76			1,059			15
Other income (expense), net		632			(1,272	)		1,074			(1,083	)
Income (loss) before expense (benefit) for income taxes	$	2,954		$	(9,995	)	$	(29,663	)	$	(44,778	)

Schedule of Gross Sales to Customers Included in Reportable Segments and All Other Customers as a Group

The following table presents the amount and percentage of gross sales to customers that represented more than 10% of the Company’s gross sales included in its two reportable segments and all other customers as a group for the three and six months ended June 30, 2020 and 2019 (in thousands, except percentages):

	For the Three Months Ended June 30,
	2020					2019
	Amount		% of Gross			Amount		% of Gross
			Sales					Sales
Customer A	$	314,288		35	%	$	366,676		37	%
Customer B		194,576		22	%		189,220		19	%
Customer C		160,814		18	%		152,057		15	%
Customer D		112,676		13	%		86,591		9	%
Other Customers		115,639		12	%		196,781		20	%
Gross Sales	$	897,993		100	%	$	991,325		100	%

	For the Six Months Ended June 30,
	2020					2019
	Amount		% of Gross			Amount		% of Gross
			Sales					Sales
Customer A	$	561,063		33	%	$	711,923		37	%
Customer B		401,853		24	%		311,277		16	%
Customer C		294,689		17	%		336,926		17	%
Customer D		197,464		12	%		161,578		8	%
Other Customers		246,447		14	%		414,787		22	%
Gross Sales	$	1,701,516		100	%	$	1,936,491		100	%

Summary of Net Sales Attributed to Geographic Sources

Geographic revenues are determined based on the country in which the Company’s customers are located.  The following table presents a summary of net sales attributed to geographic sources for the three and six months ended June 30, 2020 and 2019 (in thousands, except percentages):

	Three Months Ended June 30, 2020			Three Months Ended June 30, 2019
	Amount		% of Total Net Sales	Amount		% of Total Net Sales
United States	$	460,827	100%	$	319,404	100%
Rest of world		1,952	*		1,243	*
Net sales	$	462,779		$	320,647
*Less than 1%

	Six Months Ended June 30, 2020			Six Months Ended June 30, 2019
	Amount		% of Total Net Sales	Amount		% of Total Net Sales
United States	$	814,843	100%	$	598,612	100%
Rest of world		3,845	*		2,406	*
Net sales	$	818,688		$	601,018
*Less than 1%